Why Codexis, Inc.’s (CDXS) Stock Is Up 8.47%
As of Monday, October 19, Codexis, Inc.’s CDXS share price has surged by 8.47%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Commentary & Analysis
Why Codexis, Inc.’s (CDXS) Stock Is Down 5.15%
As of Friday, October 16, Codexis, Inc.’s CDXS share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Michael Rose
Why Codexis, Inc.’s (CDXS) Stock Is Down 6.03%
As of Monday, October 12, Codexis, Inc.’s CDXS share price has dipped by 6.03%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Codexis, Inc.’s (CDXS) Stock Is Up 8.33%
As of Wednesday, August 19, Codexis, Inc.’s CDXS share price has surged by 8.33%, which has investors questioning if this is right time to sell.Michael Rose
Why Codexis, Inc.’s (CDXS) Stock Is Down 5.35%
As of Tuesday, August 18, Codexis, Inc.’s CDXS share price has dipped by 5.35%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | CDXS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $138.0 | $3,732.9 | 25% |
|
| Shares Out (Mil) | 91.1 | 105.4 | 60% |
|
| Institutional Ownership | 87.5% | 88.3% | 55% |
|
| Float (Mil) | 82.3 | 79.7 | 57% |
|
| Beta | 2.53 | 1.19 | 96% |
|
| Avg Daily Volume (000s) | 894 | 960 | 68% |
|
| Price Change (52-week) |
(51.5%) | 90.9% | 19% |
|
| Growth | CDXS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 0.4% | 7.6% | 19% |
|
| Net Income (5yr) | (12.9%) | (11.2%) | 27% |
|
| EPS (5yr) | (4.6%) | 2.5% | 25 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.9%) | (15.0%) | 39% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.095) | ($0.425) | ($0.320) | |
| Month Ago EPS | ($0.095) | ($0.425) | ($0.320) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 2 | 1 | |
| Three Months Ago EPS | ($0.085) | ($0.355) | ($0.370) | |
| Year/Year Chg | (28.0%) | (15.8%) | (54.5%) | |
| Financials | CDXS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $78 | $800 | 24% |
|
| Net Income (TTM) (Mil) | ($31) | ($32) | 20% |
|
| EPS (TTM) | ($0.339) | ($0.300) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | $47 | 20% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $14 | 46% |
|
| Long-Term Debt (Q1) (Mil) | $62 | $284 | 41% |
|
| Enterprise Value (Q1) (Mil) | $167 | $3,582 | 25% |
|
| Valuation | CDXS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.50 | 3.70 | 71% |
|
| P/E | na | 38.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.7 | na |
|
| Ratios | CDXS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 24.3% | 47.7% | 27% |
|
| Net Margin | (39.6%) | (3.2%) | 13% |
|
| ROA | (23.8%) | (4.8%) | 19% |
|
| ROE | (69.4%) | (7.9%) | 12% |
|
| Liabilities to Assets | 72.5% | 41.8% | 68% |
|
| F-Score | 5 | 5 | 50% |
|
Codexis, Inc. did not pass any screens on 10/28/2026.
